Leprosy at IDC 2027

Leprosy primarily affects the skin and peripheral nerves but can also involve other organs such as the eyes and mucous membranes. Leprosy is transmitted through respiratory droplets from untreated individuals with the active form of the disease, although it is not highly contagious. The disease has a long incubation period, ranging from months to years, making diagnosis and treatment challenging. Leprosy presents with a spectrum of clinical manifestations, from mild skin lesions to severe nerve damage and deformities. Classification systems categorize leprosy based on the number of skin lesions and the presence of nerve involvement. Multidrug therapy (MDT), consisting of antibiotics such as rifampicin, dapsone, and clofazimine, is highly effective in treating leprosy and preventing its transmission. Early diagnosis and prompt treatment are crucial to prevent irreversible nerve damage and disabilities. Stigma and discrimination against individuals affected by leprosy have been significant challenges throughout history. Efforts to raise awareness, reduce stigma, and integrate affected individuals into society are essential for improving their quality of life and access to care. Global efforts, led by organizations like the World Health Organization (WHO) and the International Federation of Anti-Leprosy Associations (ILEP), aim to eliminate leprosy as a public health problem by providing access to early diagnosis, treatment, and rehabilitation services worldwide. Despite significant progress, leprosy remains endemic in some regions, emphasizing the importance of continued surveillance and control efforts.